73
Participants
Start Date
February 10, 2020
Primary Completion Date
October 30, 2021
Study Completion Date
December 31, 2025
Emicizumab
Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
Cliniques Universitaires St-Luc, Brussels
Charlotte Maxeke Johannesburg Hospital, Johannesburg
UZ Leuven Gasthuisberg, Leuven
Hospital Universitario la Paz, Madrid
Hemophilia of Georgia Center for Bleeding & Clotting Disorders, Atlanta
Hospital Universitario Virgen del Rocio, Seville
Indiana Hemophilia & Thrombosis center, Indianapolis
University of Michigan, C.S. Mott Children's Hospital, Ann Arbor
Universitätsklinikum Bonn, Bonn
Hopital Cardio-vasculaire Louis Pradel, Bron
Groupe Hospitalier Necker Enfants Malades, Paris
Klinikum der Universität München, Campus Innenstadt, München
Childrens Hospital LA, Los Angeles
CH de Bicetre, Le Kremlin-Bicêtre
Washington Institute for Coagulation, Seattle
Kaye Edmonton Clinic, Edmonton
Eastern Health - General Hospital, St. John's
Amsterdam UMC Location AMC, Amsterdam
Instytut Hematologii i Transfuzjologii, Warsaw
Cardiff and Vale NHS Trust, Cardiff
Royal Free Hospital, London
Great Ormond street Hospital for Children NHS Foundation Trust, London
Hoffmann-La Roche
INDUSTRY